Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma

Clinical trial NCT05512481 · RECRUITING

Trial details

NCT number: NCT05512481
Sponsor: Peking University Cancer Hospital & Institute
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Melanoma Acral Melanoma Temozolomide Apatinib Camrelizumab Neoadjuvant Pathological Response

Start date: 2022-09-13
Primary completion: 2025-12-31
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.